182 related articles for article (PubMed ID: 24506807)
21. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
22. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
Ponchon P; Elghozi JL
Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular hypertrophy: role of angiotensin II and bradykinin.
Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1996; 27 Suppl 2():S36-40. PubMed ID: 8723398
[TBL] [Abstract][Full Text] [Related]
24. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
[TBL] [Abstract][Full Text] [Related]
25. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Karlberg BE; Fyhrquist F; Grönhagen-Riska C; Tikkanen I; Ohman KP
Scand J Urol Nephrol Suppl; 1984; 79():103-6. PubMed ID: 6089307
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Sengul AM; Altuntas Y; Kürklü A; Aydin L
Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
[TBL] [Abstract][Full Text] [Related]
27. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
Schalekamp MA; Derkx FH; van den Meiracker AH
J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
[TBL] [Abstract][Full Text] [Related]
28. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
29. Modeling of angiotensin II-angiotensin-(1-7) counterbalance in disease progression in spontaneously hypertensive rats treated with/without perindopril.
Zhou X; Shang D; Zhang T; Li L; Zhou T; Lu W
Pharmacol Res; 2012 Aug; 66(2):177-84. PubMed ID: 22513176
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension.
Kohno M; Yokokawa K; Minami M; Yasunari K; Maeda K; Kano H; Hanehira T; Yoshikawa J
Metabolism; 1999 Oct; 48(10):1256-9. PubMed ID: 10535387
[TBL] [Abstract][Full Text] [Related]
31. Effects of aqueous extract of Hibiscus sabdariffa on the renin-angiotensin-aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study with lisinopril.
Nwachukwu DC; Aneke EI; Obika LF; Nwachukwu NZ
Indian J Pharmacol; 2015; 47(5):540-5. PubMed ID: 26600645
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme-derived angiotensin II formation during angiotensin II-induced hypertension.
Gonzalez-Villalobos RA; Satou R; Seth DM; Semprun-Prieto LC; Katsurada A; Kobori H; Navar LG
Hypertension; 2009 Feb; 53(2):351-5. PubMed ID: 19075090
[TBL] [Abstract][Full Text] [Related]
33. Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition.
Covi G; Sheiban I; Gelmini G; Arcaro G; Tonni S; Bolner A; Piemonte G; Lechi A
Cardiovasc Drugs Ther; 1996 Jul; 10(3):321-9. PubMed ID: 8877075
[TBL] [Abstract][Full Text] [Related]
34. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
Norton GR; Woodiwiss AJ; Hartford C; Trifunovic B; Middlemost S; Lee A; Allen MJ
Am J Hypertens; 1999 Jun; 12(6):563-71. PubMed ID: 10371365
[TBL] [Abstract][Full Text] [Related]
35. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis.
Wapstra FH; Navis G; DE Jong PE; DE Zeeuw D
J Am Soc Nephrol; 2000 Mar; 11(3):490-496. PubMed ID: 10703672
[TBL] [Abstract][Full Text] [Related]
36. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.
Duncan AM; Burrell LM; Kladis A; Campbell DJ
J Cardiovasc Pharmacol; 1996 Dec; 28(6):746-54. PubMed ID: 8961071
[TBL] [Abstract][Full Text] [Related]
37. Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats.
Liang B; Leenen FH
Br J Pharmacol; 2007 Nov; 152(6):903-14. PubMed ID: 17906684
[TBL] [Abstract][Full Text] [Related]
38. Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice.
Kai T; Shimada S; Sugimura K; Kurooka A; Takenaka T; Fukamizu A; Murakami K; Ishikawa K
J Hypertens; 1998 Dec; 16(12 Pt 2):2045-9. PubMed ID: 9886895
[TBL] [Abstract][Full Text] [Related]
39. Reduction of mean arterial pressure and proteinuria by the effect of ACEIs (Lisinopril) in Kurdish hypertensive patients in Hawler City.
Muslih AI
Glob J Health Sci; 2012 Jun; 4(5):14-9. PubMed ID: 22980373
[TBL] [Abstract][Full Text] [Related]
40. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.
Watermeyer JM; Kröger WL; O'Neill HG; Sewell BT; Sturrock ED
Biochem J; 2010 Apr; 428(1):67-74. PubMed ID: 20233165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
